JP2024529141A5 - - Google Patents

Info

Publication number
JP2024529141A5
JP2024529141A5 JP2024508570A JP2024508570A JP2024529141A5 JP 2024529141 A5 JP2024529141 A5 JP 2024529141A5 JP 2024508570 A JP2024508570 A JP 2024508570A JP 2024508570 A JP2024508570 A JP 2024508570A JP 2024529141 A5 JP2024529141 A5 JP 2024529141A5
Authority
JP
Japan
Prior art keywords
her3
cancer
contain
activating
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/072674 external-priority patent/WO2023017151A1/en
Publication of JP2024529141A publication Critical patent/JP2024529141A/ja
Publication of JP2024529141A5 publication Critical patent/JP2024529141A5/ja
Pending legal-status Critical Current

Links

JP2024508570A 2021-08-13 2022-08-12 Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 Pending JP2024529141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232883P 2021-08-13 2021-08-13
US63/232,883 2021-08-13
PCT/EP2022/072674 WO2023017151A1 (en) 2021-08-13 2022-08-12 Treatment and prevention of cancer using her3 antigen-binding molecules

Publications (2)

Publication Number Publication Date
JP2024529141A JP2024529141A (ja) 2024-08-01
JP2024529141A5 true JP2024529141A5 (enExample) 2025-08-20

Family

ID=83228993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508570A Pending JP2024529141A (ja) 2021-08-13 2022-08-12 Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防

Country Status (6)

Country Link
US (1) US20250136712A1 (enExample)
EP (1) EP4384640A1 (enExample)
JP (1) JP2024529141A (enExample)
KR (1) KR20240045281A (enExample)
CN (1) CN118119719A (enExample)
WO (1) WO2023017151A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4687972A1 (en) 2023-04-06 2026-02-11 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
WO2025056781A1 (en) * 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3-binding molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer
JP2020533269A (ja) * 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Similar Documents

Publication Publication Date Title
Ten Hoorn et al. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis
Subbiah et al. The evolving landscape of tissue‐agnostic therapies in precision oncology
Ross et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
JP2024529141A5 (enExample)
Garattini et al. Molecular classifications of gastric cancers: Novel insights and possible future applications
Bahrami et al. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer
Das et al. Promising new agents for colorectal cancer
Pietrantonio et al. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
JP2016505537A5 (enExample)
Ruiz-Banobre et al. Predictive biomarkers in metastatic colorectal cancer: A systematic review
Ross et al. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study
Mann et al. Elective neck dissection, but not adjuvant radiation therapy, improves survival in stage I and II oral tongue cancer with depth of invasion> 4 mm
Qian et al. Pembrolizumab with chemotherapy for patients with recurrent or metastatic nasal cavity and paranasal sinus squamous cell carcinoma: A prospective phase Ll study
Jordan et al. Targeted therapy in Advanced Bladder cancer-what have we learned?
Sefrioui et al. Copy number variations in DCC/18q and ERBB2/17q are associated with disease‐free survival in microsatellite stable colon cancer
Su et al. Advances and prospects of drug clinical research in colorectal cancer in 2022
Haddad et al. Adagrasib in the treatment of colorectal cancer
Cirello et al. Poorly differentiated thyroid carcinoma: Molecular, clinico-pathological hallmarks and therapeutic perspectives
Peng et al. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy
Grellety et al. A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy
Riobello et al. Next‐generation sequencing reveals remarkable genetic stability in primary and corresponding recurrent intestinal‐type sinonasal adenocarcinoma
Inokuchi et al. Cadherin 5 is a significant risk factor for hematogenous recurrence and a prognostic factor in locally advanced gastric cancer
Ichikawa et al. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer
Priya et al. Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications
Fong et al. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma